[1] E. Shtivelman, T. Hensing, G. R. Simon, P. A. Dennis, G. A. Otterson, R. Bueno, and R. Salgia, “Molecular pathways and therapeutic targets in lung cancer,” Oncotarget, vol. 5, no. 6, pp. 1392-1433, 2014.
[2] J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman, and F. Bray, “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” Int. J. Cancer, vol. 136, no. 5, pp. E359-E386, 2015.
[3] J. Rotow, and T. G. Bivona, “Understanding and targeting resistance mechanisms in NSCLC,” Nat. Rev. Cancer, vol. 17, no. 11, pp. 637-658, Oct 2017.
[4] C. J. Chen, S. L. You, L. H. Lin, W. L. Hsu, and Y. W. Yang, “Cancer epidemiology and control in Taiwan: a brief review,” Jpn. J. Clin. Oncol., vol. 32, no. suppl_1, pp. S66-S81, 2002.
[5] Y. P. Liaw, Y. C. Huang, and G. W. Lien, “Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model,” BMC Public Health, vol. 5, no. 22, pp. 8, Mar 2005.
Hsu, H. H. (2006). 晚期非小細胞肺癌患者腫瘤組織之表皮生長因子受體基因突變與化學治療結果之關聯性研究 [master's thesis, National Taiwan University]. Airiti Library. https://doi.org/10.6342/NTU.2006.03068